(3R,5S)-1-(4-fluorophenyl)-3,5-dimethylpiperazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: (3R,5S)-1-(4-fluorophenyl)-3,5-dimethylpiperazine
• 英文别名: (3S,5R)-1-(4-fluorophenyl)-3,5-dimethylpiperazine
• 化学式: C₁₂H₁₇FN₂
• 分子量: 208.279
• InChiKey: ZVQQZIKUDROJBB-AOOOYVTPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  对溴氟苯 、 2,6-dimethylpiperazine 在 tris-(dibenzylideneacetone)dipalladium(0) 、 sodium t-butanolate 、 2-二环己基磷-2',6'-二异丙氧基-1,1'-联苯 作用下， 以 1,4-二氧六环 为溶剂， 反应 0.17h， 以50%的产率得到(3R,5S)-1-(4-fluorophenyl)-3,5-dimethylpiperazine
  参考文献：
  名称：

  [EN] APPLICATIONS OF BIASED LIGANDS OF THE SEROTONIN 5-HT7 RECEPTOR FOR THE TREATMENT OF PAIN, MULTIPLE SCLEROSIS AND THE CONTROL OF THERMOREGULATION
  [FR] APPLICATIONS DE LIGANDS POLARISÉS DU RÉCEPTEUR 5-HT7 DE LA SÉROTONINE POUR LE TRAITEMENT DE LA DOULEUR, DE LA SCLÉROSE EN PLAQUES ET LE CONTRÔLE DE LA THERMORÉGULATION

  摘要：

  The present invention relates to a compound having the following formula (I) wherein: - R and R' are, independently from each other, H or (C1-C6)alkyl groups, or form together with the carbon atoms carrying them a (C6-C10)aryl group; - R2is selected from the group consisting of: H, (C1-C6)alkyl group, halo(C1-C6)alkyl group, aryl, and heteroaryl; - A1is a linker; - R'' is either a group (A-1) or a group (A-2) for use in the treatment of a brain disorder involving modified 5-HT7R-mediated signaling, especially for use in the treatment of pain or inflammation or in the treatment of multiple sclerosis, or for use to induce hypothermia.

  公开号：

  WO2022195102A1

文献信息

• Compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same
  申请人：CHONG KUN DANG PHARMACEUTICAL CORP.

  公开号：US10287255B2

  公开（公告）日：2019-05-14

  A compound of formula (I), having histone deacetylase 6 (HDAC6) inhibitory activity, wherein X, Q, N, R1, R2, L, and n are as described, isomers thereof, or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions comprising the same, a method of treating disease using the composition, and methods for preparing the novel compounds. The novel compounds according to the present invention have histone deacetylase 6 (HDAC6) inhibitory activity, and are effective for the prevention or treatment of HDAC6-associated diseases, including cancer, inflammatory diseases, autoimmune diseases, neurological diseases and neurodegenerative disorders.

  具有组蛋白去乙酰化酶 6 (HDAC6) 抑制活性的式 (I) 化合物、 其中X、Q、N、R1、R2、L和n如所述，其异构体或其药学上可接受的盐、其用于制备治疗药物的用途、包含其的药物组合物、使用该组合物治疗疾病的方法以及制备该新型化合物的方法。根据本发明的新型化合物具有组蛋白去乙酰化酶6（HDAC6）抑制活性，可有效预防或治疗HDAC6相关疾病，包括癌症、炎症性疾病、自身免疫性疾病、神经系统疾病和神经退行性疾病。
• NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
  申请人：CHONG KUN DANG PHARMACEUTICAL CORP.

  公开号：US20170096405A1

  公开（公告）日：2017-04-06

  The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, isomers thereof, or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions comprising the same, a method of treating disease using the composition, and methods for preparing the novel compounds. The novel compounds according to the present invention have histone deacetylase 6 (HDAC6) inhibitory activity, and are effective for the prevention or treatment of HDAC6-associated diseases, including cancer, inflammatory diseases, autoimmune diseases, neurological diseases and neurodegenerative disorders.